Contract Development Services

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

Tergus Pharma announced a partnership with Great Point Partners and construction of a new commercial manufacturing facility in North Carolina.

Expanded controlled substance capabilities enables Particle Sciences to develop and manufacture Schedule I–V drugs.

The company announced plans to construct a 1.3 million-ft2 integrated manufacturing center in Chengdu, China.

Recipharm Inhalation Solutions is an integrated service for inhalation products.

Samsung BioLogics will provide contract development organization services to drug developer GI Innovation.

Lonza’s SimpliFiH Services addresses bioavailability challenges with drug substance, solid-state characterization, and drug product for first-in-human studies.

Expansion at the Eberbach, Germany facility includes two Vegicap encapsulation lines, printing, inspection, and packaging capabilities.

The expansion of the CDMO’s Skokie, IL facility includes additional refrigeration and freezer space.

The companies will merge to offer a broader range of analytical data packages and regulatory support for biopharmaceuticals.

Catalent’s acquisition of Paragon Bioservices will provide expertise and in expanding gene and cell therapy markets.

The new service offers a flexible, customizable suite of products and services designed to accelerate the clinical and commercial development of gene and cell therapies.

The acquisition of CiVentiChem’s facility in the United States is expected to enhance UK-based Sterling Pharma Solutions’ chemistry development capabilities.

Catalent invests $5 million in hot melt extrusion capabilities at Somerset, NJ facility.

The partnership will enable the Applied Process Company (APC) and the National Institute for Bioprocessing Research & Training (NIBRT) to provide increased access to R&D and analytical services.

More work needed to advance drug design and development effectively.

Catalent announces investment for its Zydis ODT technology, offering increased drug load and taste-masking capabilities.

A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.

The expansion includes a new R&D laboratory and the installation of a 12,000-liter reactor at one of the company’s manufacturing facilities on its Paullo site in Milan, Italy.

Keeping abreast of the latest industry trends and retaining flexibility are key to maintaining a strong market position.

Novel analytical methods may help biologics manufacturers respond to stricter regulations on particulate matter.

Tech transfer is key to succession advancing biopharmaceutical pipeline products from research to preclinical.

Outsourcing of analytical testing and processes can help bio/pharmaceutical companies expand their product profiles.

The company will invest $4 million to increase topical and transdermal formulation development and performance testing services at its Durham, NC, facility.

The $252-million acquisition is expected to strengthen Cambrex’s position as a small-molecule CDMO across the drug lifecycle.